Clinical Trial Update: CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating CPI-0209 in combination with carboplatin for platinum-sensitive recurrent ovarian cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• CPI-0209

Snippet

Sponsor: Lan Coffman | Conditions: Recurrent Ovarian Cancer | Phase 1 | Status: RECRUITING